

John Tyler Baber, M.D.

Email: drbaberprp@gmail.com

Phone: (501) 553-9987

Research Affiliations

Offices

Preferred Research Partners, Inc.

11219 Financial Centre Parkway, Suite 320

Little Rock, AR 72211

(501) 553-9987

(501) 553-9986 FAX

Preferred Research Partners Arkansas Center for Sleep Medicine

11219 Financial Center Parkway, Suite 101

Little Rock, AR 72211

(501) 553-9987

(501) 553-9986 FAX

Education:

University of Arkansas

Fayetteville, Arkansas

University of Arkansas School of Medicine

Little Rock, Arkansas, 1975

Doctor of Medicine

Internship:

Los Angeles County – University of Southern
California Medical Center

Los Angeles, California, 1975-1976

Fellowship:

Rancho Los Amigos Hospital

Downsby, California

DIABETES, 1976-1977

Residency:

LAC-USC Medical Center

Los Angeles, California

INTERNAL MEDICINE, 1977 – 1979

Fellowship:

Baylor College of Medicine

Houston, Texas

GASTROENTEROLOGY, 1979 – 1980

Fellowship:

University of Texas – Health Science Center

Dallas, Texas

HEPATOLOGY, 1980 – 1981

Work Experience:

Solo Practice

Gastroenterology/Hepatology
1981 to Present

Preferred Research Partners, Inc.
Principal Investigator
2009 to Present

Certification/Licensure: American Board of Internal Medicine
Gastroenterology
American Board of Internal Medicine
Arkansas State Medical Board
California State Medical Board
Texas State Medical Board

Professional Organizations: Arkansas Medical Society
American Gastroenterology Association
American College of Gastroenterology
American College of Physicians
Arkansas Foundation for Medical Care
President, Arkansas Gut Club, 2001, 2002, 2003
Medicare Carrier Advisory Committee
Arkansas-Oklahoma Endoscopic Society
Chief of Gastroenterology – Baptist Medical Center,
2003 – 2006

Research Experience :

- Standard Therapeutic Assessment of Rebetrone Trial - 2000 – 2001
- Tegaserod in GI disorders – Novartis - CHTF919E2302, 2001-2002
- Tegaserod (HTP919) – Novartis - CHTF919A2306, 2003
- Diarrhea-Predominant Irritable Bowel Syndrome (27018966IBS2001) – Furiex Pharmaceuticals, 2010-2011
- Opioid Induced Constipation (D3820C00005) -AstraZeneca, 2010-2012
- Chronic Idiopathic Constipation (LUBI-SGCP-05SB07-CE), Apotex, Inc., 2011-2011
- Opioid Induced Constipation (D3820C00008) – roll-over, AstraZeneca, 2011-2012
- Chronic Idiopathic Constipation (71060001) – Anchen, Novum PRS, 2011-2012
- Chronic Idiopathic Constipation (SP304-20210) – Synergy Pharmaceuticals, 2011-2013
- Opioid Induced Constipation (1107V9221) – Shionogi, Inc., 2012-2012
- Healthy Adult Phase I (SP1031) – UCB, 2012-2012
- Diarrhea-Predominant Irritable Bowel Syndrome (27018966IBS3001) – Furiex Pharmaceuticals, 2012

- Diarrhea-Predominant Irritable Bowel Syndrome (LX1033.201-1) – Lexicon Pharmaceuticals, 2012
- Diarrhea-Predominant Irritable Bowel Syndrome (ASMP3001) – Tioga Pharmaceuticals, 2012-2013
- Crohn's Disease (TU100P2T2) – Tsumura, 2012
- Crohn's Disease (CNDO201-003) – Coronado Biosciences, 2012
- Gastroesophageal Reflux Disease (SPD557-206) – Shire, 2012
- Chronic Idiopathic Constipation (DRGL-USG01-L/2012) – Dr. Reddy's Laboratories, 2012
- Chronic Back Pain & Opioid Induced Constipation (ONU3705) – Purdue Pharma, 2013
- Opioid Induced Constipation (5945-SOIC-12-05) – Cubist Pharmaceuticals, 2013
- Chronic Idiopathic Constipation (00080) – Ferring Pharmaceuticals, 2013
- Opioid Induced Constipation (5945-OIC-12-04) – Cubist Pharmaceuticals, 2013
- Chronic Idiopathic Constipation (00081) – Ferring Pharmaceuticals, 2013
- Diarrhea-Predominant Irritable Bowel Syndrome (NAK-07) – Menarini Pharmaceuticals, 2013
- Chronic Idiopathic Constipation (CIC) – Synergy Pharmaceuticals, Inc. – SP304203-01 (CIC-OLE), 2013
- Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy – Shionogi, Inc. – 1315V9232, 2013
- Chronic Idiopathic Constipation – Synergy Pharmaceuticals, Inc. – SP304203-00 (CIC3), 2013
- Diabetic Gastroparesis – Evoke Pharma – METO-IN-003, 2014
- Diabetic Gastroparesis – Evoke Pharma – METO-IN-004, 2014
- Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk – Eisai Inc. – APD356-G000-401 (CAMELLIA), 2014
- Active Moderate Crohn's Disease – Salix Pharmaceuticals, Inc. – RECD3125, 2014
- Gastric Emptying Time in Diabetic Subjects with Gastroparesis – Targacept – TC-6499-12-CLP-005, 2014
- Diabetic Gastroparesis – Rhythm Pharmaceuticals – RM-131-009, 2015
- Diabetic or Idiopathic Gastroparesis – Theravance– 0099, 2015

- Irritable Bowel Syndrome-Constipation – Synergy Pharmaceuticals, Inc. – SP304203-04, 2015
- Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic Constipation – Forest Research Institute, Inc. – LIN-MD-10, 2015
- Ulcerative Colitis – Gilead – GS-US-326-1100, 2015
- Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000174, 2016
- Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000175, 2016
- Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) – IDN-6556-12, 2016
- Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) – SP304203-06, 2016
- Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome – 1VIT14037, 2016
- Braintree Laboratories, Chronic Constipation – BLI400-302, 2016
- Braintree Laboratories, Opioid Induced Constipation – BLI801-203, 2016
- Applied Proteomics – Colorectal Cancer Screening – API-CP001, 2016
- Takeda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – TAK906-1002, 2017
- Allergan – Diabetic Gastroparesis – RLM-MD-01, 2017
- Braintree Laboratories, Bowel Prep for Colonoscopy – BLI4700-302, 2017
- Vanda Pharmaceuticals, Inc. – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-2301, 2017
- Allergan – Diabetic Gastroparesis – RLM-MD-04, 2017
- Freenome Holdings, Inc., Health Decisions – Colorectal Cancer Screening, FRE-001, 2018
- Allergan – Diabetic Gastroparesis – RLM-MD-03, 2018
- 2018: Allergan – Diabetic Gastroparesis – 3071-305-020
- 2018: Ironwood Pharmaceuticals – GERD – C3718-302
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003
- 2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64
- 2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66

- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270
- 2019: OrphoMed – Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) – OM-201
- 2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201
- 2020: Guardant Health – Colorectal Cancer Screening – 02-GI-002 ECLIPSE
- 2021: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-201
- 2021: Revolo Pharmaceuticals – Eosinophilic Esophagitis – RVLO 121-04
- 2022: 89 Bio – NASH – BIO89-100-122
- 2022: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-301
- 2022: Braintree Laboratories – Erosive Esophagitis – BLI5100-301
- 2022: Braintree Laboratories – Non-erosive Reflux Disease – BLI5100-302
- 2022: Ellodi Pharmaceuticals, L.P. – Eosinophilic Esophagitis – SP-1011-005
- 2022: Hepion Pharmaceuticals. – Non-alcoholic Steatohepatitis – HEPA-CRV431-207
- 2022: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-102
- 2023: CinDome – Adult Diabetic Gastroparesis – CIN-102-123
- 2023: Braintree Laboratories – Gastroesophageal Reflux Disease – BLI5100-303
- 2023: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-103
- 2024: Phathom – Pediatric GERD – VPED-104
- 2024: Vanda Pharmaceuticals - SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS – VP-VLY-686-3303-P59
- 2025: Cindome Pharma, Inc. - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis – CIN-102-124

- 2025: Phathom Pharmaceuticals, Inc. - A Phase 2, Randomized, Double-Blind, Multi-Center, 3-Part Study in Adult and Adolescent Subjects with Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 10 mg and 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 10 mg and 20 mg Up to 52 Weeks – EoE-201
- 2025: Eli Lilly & Company - An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart and Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis – I7J-MC-DSAG
- 2025: Sanofi-Aventis - An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis – EFC18325
- 2025: Sanofi-Aventis - A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease – EFC18326
- 2025: Sanofi-Aventis - A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's disease – EFC18327
- 2025: Sanofi-Aventis - A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis – EFC18359
- 2025: Mirador Therapeutics, Inc. - A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD – MT-100-201/PROBEUC/PROBECD

Personal:

Name – John Tyler Baber, M.D.
 Birthplace – St. Louis, Missouri
 Birth Date – June 26, 1950
 Email – drbaberprp@gmail.com

Business Address:

CHI St. Vincent Gastroenterology Clinic – Little Rock
 417 North University
 Little Rock, AR 72205

Preferred Research Partners, Inc.
 11219 Financial Center Parkway
 Suite 320
 Little Rock, AR 72211